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accumulation of mutated alleles in MF transformation
of PV. Finally, in PET-MF the median allele burden was
57%, a value significantly greater than the 26% of a
control group of ET patients from our Institution.13 This
result suggests that accumulation of mutant V617F alle-
les is also a mechanism of evolution toward MF in
JAK2V617F mutated ET patients.
Apart from a significantly lower platelet count
(p=0.04) in JAK2V617F mutated patients, no other
meaningful correlation with JAK2V617F mutational
status could be ascertained (Table 1). The V617F mutat-
ed or unmutated patients were also comparable in
terms of spleen size, incidence of thrombosis, inci-
dence of major hemorrhages (2 patients in each group,
all from previous ET), and the rate of AML transforma-
tion which occurred in 2/16 JAK2 unmutated and 6/49
JAK2V617F mutated patients (12.5% and 12.2%
respectively) (data not shown). The correlation between
V617F allele burden and clinical presentation and prog-
nosis was also studied by dividing patients into quar-
tiles of V617F allele distribution. We grouped together
the first two quartiles because of the low number of
patients included (Table 1), and we found that V617F
allele burden was positively correlated with age, white
blood cell count and circulating CD34+ cell count (all
with a p value <0.05). However, there was no statisti-
cally significant correlation with clinical characteristics,
i.e. spleen size, thrombosis, hemorrhages, nor with the
rate of patients who evolved to AML (3 of whom were
in the two first quartiles, one and 2 in the third and
fourth quartile respectively). 
To the best of our knowledge, this is the first study
specifically addressing the clinical relevance of
JAK2V617F mutation in patients who evolved to MF
from a previous PV or ET. The data presented herein
prompted us to conclude that neither the JAK2V617F
mutational status nor the V617F allele burden seem to
have relevance for disease phenotype or prognosis in
this setting of patients. However, the relatively short
follow-up might have prevented the discovery of corre-
lations of JAK2V617F mutational status with clinical
events occurring late in the history of these disorders,
in particular for the evolution to AML. This will require
larger patient series with a much longer observation.
Paola Guglielmelli,1,2 Giovanni Barosi,3 Lisa Pieri,1,2
Elisabetta Antonioli,1,2 Alberto Bosi,1,2
and Alessandro M. Vannucchi1,2
1Unità Funzionale di Ematologia, Dipartimento di Area Critica,
Università degli Studi, Firenze; 2Istituto Toscano Tumori, Firenze;
3Unità di Epidemiologia Clinica, Centro per lo Studio della
Mielofibrosi, Fondazione IRCCS Policlinico San Matteo,
Pavia, Italy
Key words: myelofibrosis, JAK2V617F mutation, polycythemia vera,
essential thrombocythemia
Correspondence: Alessandro M. Vannucchi, MD, Department
of Hematology, University of Florence, 50134 Florence, Italy. 
Phone: international +39.055.7947688. Fax: international
+39.055.7947688. E-mail: amvannucchi@unifi.it 
Funding: the study was supported by Ministero della Università e
Ricerca (COFIN 2006067001_003), Istituto Toscano Tumori,
and institutional funds from Università di Firenze (ex-60%).
Citation: Guglielmelli P, Barosi G, Pieri L, Antonioli E, Bosi A,
Vannucchi AM. JAK2V617 mutational status and allele burden
have little influence on clinical phenotype and prognosis in patients
with post-polycythemia vera and post-essential thrombocythemia
myelofibrosis. Haematologica 2009; 94:144-146. 
doi: 10.3324/haematol.13721
References
1. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T,
Hanson CA, et al. Proposals and rationale for revision of
the World Health Organization diagnostic criteria for poly-
cythemia vera, essential thrombocythemia, and primary
myelofibrosis: recommendations from an ad hoc interna-
tional expert panel. Blood 2007;110:1092-7.
2. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani
L, Antonioli E, et al. Anaemia characterises patients with
myelofibrosis harbouring Mpl mutation. Br J Haematol
2007;137:244-7.
3. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A,
Guerini V, Barosi G, et al. Characteristics and clinical corre-
lates of MPL 515W>L/K mutation in essential thrombo-
cythemia. Blood 2008;112:844-7.
4. Beer PA, Campbell P, Scott LM, Bench AJ, Erber WN,
Bareford D, et al. MPL mutations in myeloproliferative dis-
orders: analysis of the PT-1 cohort. Blood 2008;112:141-9.
5. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A,
Tefferi A. Clinical correlates of JAK2V617F presence or
allele burden in myeloproliferative neoplasms: a critical
reappraisal. Leukemia 2008:1299-307.
6. Campbell PJ, Griesshammer M, Dohner K, Dohner H,
Kusec R, Hasselbalch HC, et al. V617F mutation in JAK2 is
associated with poorer survival in idiopathic myelofibrosis.
Blood 2006;107:2098-100.
7. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA,
Li CY, et al. The JAK2(V617F) tyrosine kinase mutation in
myelofibrosis with myeloid metaplasia: lineage specificity
and clinical correlates. Br J Haematol 2005; 131:320-8.
8. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM,
Guglielmelli P, Antonioli E, et al. JAK2 V617F mutational
status predicts progression to large splenomegaly and
leukemic transformation in primary myelofibrosis. Blood
2007;110:4030-6.
9. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, et
al. Low JAK2V617F allele burden in primary myelofibrosis,
compared to either a higher allele burden or unmutated sta-
tus, is associated with inferior overall and leukemia-free
survival. Leukemia 2008;22:756-61.
10. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E,
Pascutto C, et al. Relation between JAK2 (V617F) mutation
status, granulocyte activation, and constitutive mobiliza-
tion of CD34+ cells into peripheral blood in myeloprolifer-
ative disorders. Blood 2006;107:3676-82.
11. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ,
Verstovsek S, et al. Proposed criteria for the diagnosis of
post-polycythemia vera and post-essential thrombo-
cythemia myelofibrosis: a consensus statement from the
international working group for myelofibrosis research and
treatment. Leukemia 2008;22:437-8.
12. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G,
Pancrazzi A, Ponziani V, et al. Prospective identification of
high-risk polycythemia vera patients based on
JAK2(V617F) allele burden. Leukemia 2007;21:1952-9.
13. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A,
Longo G, et al. Influence of JAK2V617F allele burden on
phenotype in essential thrombocythemia. Haematologica
2008;93:41-8.
High-dose therapy and autologous stem cell trans-
plantation versus conventional therapy for
patients with advanced Hodgkin’s lymphoma
responding to front-line therapy: long-term results
The inclusion of high-dose therapy/autologous stem
cell transplantation (HDT/ASCT) in the initial treatment
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(HL) has been a matter of debate for the last two
decades. In 1991, Carella et al.1 published a pilot study
of HDT and ASCT in patients with unfavorable HL
who had achieved CR with conventional-dose therapy.
In an attempt to improve the cure rate of advanced,
unfavorable HL and to reduce the risk of relapse after
initial response, in April 1993 we started a large co-oper-
ative study comparing HDT/ASCT versus conventional
chemotherapy (CHT) in patients in CR or PR after four
courses of ABVD or other doxorubicin-containing regi-
mens. 
Between April 1993 and December 2000, 208 patients
were registered on the trial; among these, 163 fully
complied with the protocol requests and were random-
ly assigned to receive HDT plus ASCT (HDT-ASCT
Arm, 83 patients) versus four additional courses of the
same standard chemotherapy used in the induction
phase (CHT Arm, 80 patients). Unfavorable HL was
defined using a Strauss-derived system.2 The details rel-
ative to patients’ characteristics, entry criteria, treat-
ment protocol and statistical analysis have been previ-
ously described.3 At the end of the treatment program,
92% of patients in HDT-ASCT arm and 89% in CHT
arm achieved a CR (p=0.6). The 5-year FFS rates were
75% (95% confidence interval [CI], range 65-85) in the
HDT-ASCT arm and 82% (95% CI, range 73-90) in the
CHT arm (p=0.4). The 5-year OS rates were 88% (95%
CI, range 80-96) in the HDT-ASCT arm and 88% (95%
CI, range 79-96) in the CHT Arm (p=0.99). The 5-year
RFS rates were 88% in the HDT-ASCT arm (95% CI,
range 80-96) and 94% in the CHT arm (95% CI, range
88-100), and there was no statistical difference (p=0.3).
We now present the updated results of this study after
an extended follow-up period of four years (median fol-
low-up of alive patients is currently 107 months, range
9-172). In Table 1 we present a flow diagram showing
what became of all the patients assigned to each arm
and, finally, 10-year OS, RFS and FFS.
The 10-year OS were 85% (95% CI, range 78-90) and
84% (95% CI, range 77-89) for patients who underwent
HDT-ASCT or CHT respectively. Also after an extend-
ed follow-up, no significant difference emerged
between the two arms (p=0.7) (Figure 1A). Since the
Hasenclever prognostic score has emerged to be more
robust than the Strauss prognostic system, we also per-
formed the analysis of our data according to the former.4
We compared outcome in the two arms but we found
no statistical difference [10 year OS: IPS 0-2 (49 pts.):
98% (ASCT), 84% (CHT), p=0.5; IPS 3-6 (84 pts.): 85%
(ASCT), 88% (CHT), p=0.8; 10 year FFS: IPS 0-2 (49
pts.): 84% (ASCT), 75% (CHT), p=0.4; IPS 3-6 (84 pts.):
79% (ASCT), 83% (CHT), p=0.8]. The 10-year FFS was
79% (95% CI, range 72-85) for patients in the HDT-
ASCT arm and 75% (95% CI, range 67-82) for patients
in the CHT arm (p=0.8) (Figure 1B). No difference in late
toxicity was observed between the two groups: overall
late toxicity consisted of 2 bone necrosis in the
HDT/ASCT arm and 2 second malignancies, (cancer of
the testis with gastric metastases and one a MDS/AML).
In addition to these failures, 2 patients have died from a
second malignancy (both lung cancers), one in each arm.
Therefore, after a median follow-up of 107 months,
our data definitely support the view that for patients
responding to initial conventional CHT the consolida-
tion with HDT/ASCT is not superior to consolidation
with conventional-dose therapy and, most importantly,
confirm that HDT/ASCT as consolidation therapy
should no longer be offered to these patients. 
Another relevant issue of our study was the evalua-
tion of safety of an early use of HDT followed by
ASCT. According to published data, 2% of deaths
caused by HDT/ASCT toxicity can be expected.5 In the
present study, only one toxic death occurred thus con-
firming the increasing safety of this procedure when
performed in the initial course of the disease. Of course,
these conclusions refer to a population diagnosed with
HL in the pre-FDG-PET era, when the treatment deci-
sions were based on adverse risk factors present at time
of diagnosis, before treatment was started. Currently,
we have more chance of reducing treatment related tox-
icities and of avoiding undue treatment in selected
groups of patients who can be cured with standard-dose
regimens. Using FDG-PET scan in the evaluation of
treatment response in HL, the negative predictive value
is high (81-100%) showing the ability of FDG-PET to
identify patients with excellent prognosis.6-8 To these
patients we can reasonably apply the conclusions of our
study, that is that they do not benefit from an early
intensification with HDT and ASCT. The ongoing
worldwide trials will most probably provide a definite
answer to the role of early PET in the selection of
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Figure 1. (A). Overall survival and (B) failure-free survival of all
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patients at high risk of relapse candidates for intensifica-
tion with HDT and ASCT. 
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Clinical relevance of MDM2 SNP 309 and TP53
Arg72Pro in follicular lymphoma
Tumor protein 53 (TP53) is critical to cell cycle control
and is the most common mutational target in germinal
center lymphomas. However, these mutations occur
infrequently at diagnosis (<10%) in follicular lymphoma
(FL), and are more commonly associated with disease pro-
gression or transformation to more aggressive histology.1-
4 Inactivation of TP53 may also occur by upregulation of
the human homolog of the Murine Double Minute 2 protein
(MDM2), which targets TP53 for degradation by the pro-
teasome and is frequently amplified in FL and other
malignancies; indeed Mdm2 haplo-insufficiency in mice
leads to enhanced TP53 function with delayed onset of
lymphoma.5 While many studies have examined the
genomic events targeting these loci, less is known as to
the functional role of polymorphic variants at the MDM2
or TP53 loci. The single nucleotide polymorphisms
(SNPs), MDM2 SNP 309 and TP53 Arg72Pro, have at least
in some studies an additive effect on cancer susceptibility
with MDM2 SNP 309 also predicting advanced disease at
diagnosis.6 Consequently, we investigated the impact of
MDM2 SNP 309 and TP53 Arg72Pro on the clinical out-
come of FL. MDM2 SNP 309 characterizes a T>G substi-
tution at nucleotide 309 of intron one and leads to higher
MDM2 mRNA and protein expression with lower apop-
totic response.  Significantly, homozygosity for the G
allele correlates with earlier onset of de novo diffuse large
B-cell lymphoma (DLBCL) in females7 Its role in CLL is
less clear as two recent studies provide contrasting
results.8,9 TP53 Arg72Pro is a non-synonymous SNP
involving G>C substitution at nucleotide 466 of exon 4 in
Table 1. Flow diagram showing the updated results of randomized patients. 
HDT/ASCT arm CHT arm
(83) (80)
Complete remission 76 (92%) 71 (89%)
Deaths
Overall 14 12
During extended follow-up 6 3
Relapses
Overall 8 7
During extended follow-up − 3
Failures*
Overall 20 18
During extended follow-up 1 4
Median follow-up, 108 106
months (alive pts.) (42-172) (9-158)
10-year OS 85% 84% p=0.7
(95% C.I. 78-90) (95% C.I. 77-89)
10-year RFS 88% 89% p=0.8
(95% C.I. 81-95) (95% C.I. 83-93)
10-year FFS 79% 75% p=0.8
(95% C.I. 72-85) (95% C.I. 67-82)
*CR not achieved, relapse after CR,death in CR, second tumor.
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